routine blood cell counter sysmex k4500 (Sysmex Corporation)
90
Structured Review
Sysmex Corporation
routine blood cell counter sysmex k4500
Routine Blood Cell Counter Sysmex K4500, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/routine+blood+cell+counter+sysmex+k4500/xe+2100/pm20889993-24-10-14
Average 90 stars, based on 1 article reviews
Routine Blood Cell Counter Sysmex K4500, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/routine+blood+cell+counter+sysmex+k4500/xe+2100/pm20889993-24-10-14
Average 90 stars, based on 1 article reviews
routine blood cell counter sysmex k4500 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction. Article Snippet: Background Iron and (stainless) steel are potent platelet aggregation activators, and may be involved in stent thrombosis, a serious complication after intracoronary stenting.. Current platelet function tests are suboptimal, because of inappropriate agonists and/or lack of reproducibility.. We tested the feasibility and reproducibility of a novel platelet function test using stainless steel as an agonist and compared it with other platelet function tests. Article Title: Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. Article Snippet: with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome Jaap Jan J. Smit, MD, Nicolette M.S.K.J.. Ernst, MD, Robbert J. Slingerland, PhD, J.J. Evelien Kolkman, MSc, Harry Suryapranata, PhD, Jan C.A.. Hoorntje, PhD, Jan Henk Dambrink, PhD, Jan Paul Ottervanger, PhD A.T. Marcel Gosselink, PhD Menko Jan de Boer, PhD and Arnoud W.J. van’t Hof PhD, on behalf of the On-TIME study group Zwolle, The Netherlands Article Title: Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Article Snippet: Objective To assess whether prehospital initiation of high-dose tirofiban in addition to high-dose clopidogrel results in more adequate inhibition of platelet aggregation (IPA) and better clinical outcome after primary percutaneous coronary intervention (PCI).. Methods Prespecified two-centre substudy of the prospective, international, multicentre, placebo controlled Ongoing Tirofiban in Myocardial Infarction Evaluation trial 2 (On-TIME-2 trial).. 648 of 964 (67%) patients in the On-TIME-2 trial with ST elevation myocardial infarction undergoing primary PCI were studied. Indirect Immunoperoxidase Assay:Article Title: Day 2 – Sunday 31 August 2003 Article Snippet: Objective: Cardiac hypertrophy is a complex phenotype induced by a number of stimuli and may lead to cardiomyopathy and heart failure.. Present knowledge suggests that cell cycle regulatory proteins take part in the development of hypertrophy.. We have investigated the activation and regulation of the E2F transcription factor during the hypertrophic response. |